Toshiki Kuno

Dr. Toshiki Kuno


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Vaccine
Verified
Journal Article
Closed access
AWAtsuyuki Watanabe
Atsuyuki Watanabe
MIMasao Iwagami
Masao Iwagami
JYJun Yasuhara
Jun Yasuhara
HTHisato Takagi
Hisato Takagi
TKToshiki Kuno
Toshiki Kuno

1 January 2020 in JACC
Verified
Journal Article
Closed access
TKToshiki Kuno
Toshiki Kuno
HTHisato Takagi
Hisato Takagi
TATomo Ando
Tomo Ando
TSTakehiro Sugiyama
Takehiro Sugiyama
SMSatoshi Miyashita
Satoshi Miyashita
SBSripal Bangalore
Sripal Bangalore

12 June 2022 in Respirology
Verified
Journal Article
Closed access
AWAtsuyuki Watanabe
Atsuyuki Watanabe
MSMatsuo So
Matsuo So
MIMasao Iwagami
Masao Iwagami
KFKoichi Fukunaga
Koichi Fukunaga
HTHisato Takagi
Hisato Takagi
TKToshiki Kuno
Toshiki Kuno

22 March 2021 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
MSMatsuo So
Matsuo So
HKHiroki Kabata
Hiroki Kabata
KFKoichi Fukunaga
Koichi Fukunaga
HTHisato Takagi
Hisato Takagi
TKToshiki Kuno
Toshiki Kuno
Background: The coronavirus disease 2019 (COVID-19) causes a wide spectrum of lung manifestations ranging from mild asymptomatic disease to severe respiratory failure. We aimed to clarify the characteristics of radiological and functional lung sequelae of COVID-19 patients described in follow-up period. Method: PubMed and EMBASE were searched on January 20th, 2021 to investigate characteristics of lung sequelae in COVID-19 patients. Chest computed tomography (CT) and pulmonary function test (PFT) data were collected and analyzed using one-group meta-analysis. Results: Our search identified 15 eligible studies with follow-up period in a range of 1–6 months. A total of 3066 discharged patients were included in these studies. Among them, 1232 and 1359 patients were evaluated by chest CT and PFT, respectively. The approximate follow-up timing on average was 90 days after either symptom onset or hospital discharge. The frequency of residual CT abnormalities after hospital discharge was 55.7% (95% confidential interval (CI) 41.2–70.1, I2 = 96.2%). The most frequent chest CT abnormality was ground glass opacity in 44.1% (95% CI 30.5–57.8, I2 = 96.2%), followed by parenchymal band or fibrous stripe in 33.9% (95% CI 18.4–49.4, I2 = 95.0%). The frequency of abnormal pulmonary function test was 44.3% (95% CI 32.2–56.4, I2 = 82.1%), and impaired diffusion capacity was the most frequently observed finding in 34.8% (95% CI 25.8–43.8, I2 = 91.5%). Restrictive and obstructive patterns were observed in 16.4% (95% CI 8.9–23.9, I2 = 89.8%) and 7.7% (95% CI 4.2–11.2, I2 = 62.0%), respectively. Conclusions: This systematic review suggested that about half of the patients with COVID-19 still had residual abnormalities on chest CT and PFT at about 3 months. Further studies with longer follow-up term are warranted.

25 April 2021 in Mycoses
Verified
Journal Article
Open access
PDF file
HMHayato Mitaka
Hayato Mitaka
TKToshiki Kuno
Toshiki Kuno
HTHisato Takagi
Hisato Takagi
PPParu Patrawalla
Paru Patrawalla
COVID‐19‐associated pulmonary aspergillosis (CAPA) has been reported worldwide. However, basic epidemiological characteristics have not been well established. In this systematic review and meta‐analysis, we aimed to determine the incidence and mortality of CAPA in critically ill patients with COVID‐19 to improve guidance on surveillance and prognostication. Observational studies reporting COVID‐19‐associated pulmonary aspergillosis were searched with PubMed and Embase databases, followed by an additional manual search in April 2021. We performed a one‐group meta‐analysis on the incidence and mortality of CAPA using a random‐effect model. We identified 28 observational studies with a total of 3148 patients to be included in the meta‐analysis. Among the 28 studies, 23 were conducted in Europe, two in Mexico and one each in China, Pakistan and the United States. Routine screening for secondary fungal infection was employed in 13 studies. The modified AspICU algorithm was utilised in 15 studies and was the most commonly used case definition and diagnostic algorithm for pulmonary aspergillosis. The incidence and mortality of CAPA in the ICU were estimated to be 10.2% (95% CI, 8.0–12.5; I2 = 82.0%) and 54.9% (95% CI, 45.6–64.2; I2 = 62.7%), respectively. In conclusion, our estimates may be utilised as a basis for surveillance of CAPA and prognostication in the ICU. Large, prospective cohort studies based on the new case definitions of CAPA are warranted to validate our estimates.

23 October 2023 in JACC
Verified
Journal Article
Closed access
TKToshiki Kuno
Toshiki Kuno
YKYuko Kiyohara
Yuko Kiyohara
AMAkiko Maehara
Akiko Maehara
HUHiroki A. Ueyama
Hiroki A. Ueyama
PKPolydoros N. Kampaktsis
Polydoros N. Kampaktsis
SBSripal Bangalore
Sripal Bangalore